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Abstract
Postmenopausal osteoporosis is a silent systemic progressive disease 
characterised by a decrease in bone mass per unit volume, compromising 
the physical strength of the skeleton and enhancing susceptibility to 
fractures on minor trauma. The progressive loss of bone tissue occurs as 
a result of an imbalance between bone formation and bone resorption 
subsequent to oestrogen deficiency.  The aim of this overview is to 
shed light on the pathophysiology, aetiology and diagnostic techniques 
for this metabolic bone disorder. It demonstrates current treatment 
options and evaluates the emerging pharmacological therapies in the 
management of postmenopausal osteoporosis.
Overview of the pathogenesis 
and management of 
postmenopausal osteoporosis
Educational aims
•	 To review the pathogenesis of osteoporosis
•	 To identify risk factors for postmenopausal osteoporosis
•	 To update healthcare professionals on the management of postmenopausal osteoporosis 
Introduction
Osteoporosis is a silent systemic progressive 
disease characterised by a decrease in bone 
mass per unit volume, compromising the 
physical strength of the skeleton and enhancing 
susceptibility to fractures on minor trauma.1, 2  
Osteoporosis can be classified  into 2 
categories
•	 Primary  osteoporosis (Type I) refers 
to the idiopathic form of osteoporosis 
occurring as a consequence of the normal 
process of aging.3,4 Postmenopausal 
osteoporosis affects one third of all women 
and is caused by a decline in sex hormones 
as a consequence of menopause.5,6,7
•	 Secondary   osteoporosis (Type II)  
occurs  as  a result of chronic conditions 
such  as    rheumatoid arthritis  and   
diabetes mellitus,  adverse effects  of  
medications or nutritional deficiencies 
which enhance bone loss and interfere with 
peak bone  mass  attained at maturity.8 
Aetiology
Bone remodelling is a lifelong continuous 
process whereby bone resorption and bone 
formation are kept at a balance so as to 
maintain a normal bone mass. At a cellular level, 
bone remodelling is dependent on osteoblasts 
and osteoclasts whilst osteocytes and bone 
lining cells maintain homeostasis by controlling 
the bone’s microenvironment.9 Osteoclasts, 
originating from the monocyte macrophage 
lineage, are responsible for bone resorption and 
reside on calcified bone surface.10 Osteoblasts, 
originating from precursors of mesenchymal 
cells, are responsible for bone formation and 
mineralisation of bone matrix by deposition of 
the organic matrix called osteoid.11 
In the presence of stress or microdamage, 
osteocytes will stimulate the remodelling 
cycle and start the process of bone repair. 
Upon stimulation, osteoclasts assemble on 
the bones’ surface held tightly by fimbriated 
organelles and secrete proteolytic enzymes 
initiating the process of bone resorption and 
bone degradation.10,12  Following resorption, a 
process known as formation follows whereby 
osteoblasts secrete both the matrix vesicles 
which are highly rich in the enzyme alkaline 
phosphatase, and collagen  to produce an 
unmineralised matrix known as osteoid. Upon 
osteoid maturation, crystals of hydroxyapatite 
are deposited on the matrix vesicles leading to 
bone mineralisation.12,13  This whole process of 
bone remodelling occurs every 3 to 6 months.3,5 
At maturity when peak bone mass is 
reached, an imbalance exists between bone 
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resorption by osteoclasts and bone formation by 
osteoblasts, forming the basis of menopause-
related bone loss leading to accelerated bone 
loss and skeletal fragility.5 It is proposed that 
oestrogen deficiency results in a rise in the  
number of osteoclasts and an increase in the 
depth of resorption, stimulating more bone 
turnover sites and thus increasing the number 
of bone remodelling units.2,5,14 Oestrogen 
deficiency results in weakening of  the response 
of osteoblasts to mechanical stimuli hence 
affecting bone repair.15 This is known as 
uncoupling of the bone remodelling process16 
leading to low bone mass and microarchitectural 
disintegration of bone tissue, with a resultant 
increase in bone weakness.17 
Signs and symptoms
Postmenopausal osteoporosis is referred to as a 
silent epidemic as bone loss itself produces no 
symptoms until a fracture occurs. Women with 
osteoporosis have a higher incidence of fractures 
than non-osteoporotic women when exposed 
to equal trauma.18 A fracture is classified as 
osteoporotic if it occurs in individuals over 50 
years of age and is associated with low bone 
mineral density (BMD) at the fracture site.15 The 
most frequent fractures are those occurring at 
the wrist (most frequently the distal radius), 
vertebrae and hip (proximal femur).14,19 
Colles’ fracture is a fracture of the distal 
radius with dorsal displacement producing the 
“dinner fork deformity”. This type of fracture 
occurs due to a fall on the outstretched hand.14 
Fracture at the wrist is regarded as an early 
warning sign for the presence of postmenopausal 
osteoporosis.2
Vertebral osteoporotic fractures affect 
approximately one in four postmenopausal 
women.20 These occur when one or more vertebra 
of the spinal column (most commonly in the 
T8 to L4 regions) collapse spontaneously with 
normal activities such as coughing or sneezing.21 
This results in shortening of the length of 
the spinal column and in the development of 
the characteristic dorsal kyphosis known as 
dowager’s hump.3 
Fracture of the neck of the femur is the 
most severe repercussion of postmenopausal 
osteoporosis. Pain, disability and hospitalisation 
are among the consequences of such a fracture.22 
Surgical complications appear in one third of 
the patients.2 Hip fractures cause 20% of the 
affected individuals to die within a year19, 40% 
become incapable to carry out their daily needs, 
20% bedridden, whilst 20% may require to stay 
in nursing homes for some period of time.22 
Risk factors 
Risk factors for osteoporosis are those which 
affect peak bone mass, influence bone loss or else 
interfere in some way with calcium homeostasis.5 
A single risk factor will not cause osteoporosis 
but in combination these are known to increase 
the rate of bone loss.16  
Unmodifiable risk factors include:
•	 Age 
Bone mineral density is on the increase 
until the mid-twenties when the peak bone 
density is reached. However, after a period 
of stability, it starts to decline as from 
the mid-forties. The rate of bone loss in 
premenopausal women is less than 1% each 
year. However, in the early postmenopausal 
years, a phase of accelerated bone loss 
ensues in which the rate of bone loss may 
reach a maximum of 5% each year. Bone 
mineral density declines with advancing age 
resulting in a higher risk of osteoporotic 
fracture.5,6
•	 Gender 
Females are at a higher risk for osteoporosis 
due to smaller bones and consequently lower 
peak bone mass when compared to males. 
Additionally, in menopause as a result of a 
decline in the ovarian hormones, women tend 
to lose bone at a faster rate than males.23
•	 Ethnicity 
Postmenopausal osteoporosis is more 
common in white or Asian women than 
among the dark-skinned  population.23
•	 Family history 
Being a polygenic disorder, several genes 
are thought to have a role in determining 
women’s rate of bone loss and the 
inflammatory bone turnover.5,24
•	 Reproductive History 
An exponential rate of bone loss occurs after 
early or surgical menopause which then 
decreases after 4 years to a rate equal to that 
of premenopausal women.5 
Multiple reproductive factors such as parity, 
age at menarche and menopause, duration of 
menopause, age at first pregnancy and length of 
lactation period are known to affect bone mineral 
density with their effect being debatable. Gur et 
al., reported that the  number of pregnancies is 
inversely related to BMD and this is correlated 
with the calcium demands during pregnancy. In 
contrary to this, other studies reported that high 
parity is protective against osteoporosis as a 
result of a rise in circulating level of oestrogen 
in the third trimester of pregnancy, weight gain 
and elevated calcium intake.  Interpregnancy 
interval period of less than 2 years, especially if 
less than 1 year, is associated with increased 
risk for osteoporosis. Pregnancy before 27 years 
of age is negatively correlated to BMD as a 
result of competition between mother and baby 
for calcium adversely affecting the mother’s 
skeleton. The effect of breastfeeding on BMD is 
controversial.25,26
Potentially modifiable risk factors include: 
•	 Body mass index 
Overweight individuals exert more physical 
stress on the skeleton. However as 
overweight individuals possess a greater 
number of fat cells, more oestrone is 
produced through peripheral conversion 
of androstenedione in adipose tissue. This 
elevated oestrogen level may protect such 
women from postmenopausal osteoporosis 
by slowing the rate of bone loss.5 Low body 
mass index increases the risk for fractures, 
especially hip fractures.  The correlation 
between BMI and fracture risk is non-linear 
with BMI <20kg/m2 linked with higher risk 
of fractures.27
•	 Dietary Calcium levels and Vitamin D 
Diet deficient in calcium results in a decline 
in bone formation causing low peak bone 
mass and exerts no effect on the rate of 
bone loss.28 Vitamin D aids in calcium 
absorption and in preserving bone integrity.5
•	 Caffeine and Alcohol 
Caffeine and alcohol both promote calcium 
transfer from bone to plasma.  
•	 Exercise 
Sedentary lifestyle increases the risk of 
osteoporosis. The bone density in the spine 
and the hip are improved following fast 
walking exercise by promoting the action of 
osteoblasts.28
•	 Smoking 
Decreased bone mass and higher rate 
of bone loss are observed in cigarette 
smokers.23 Smoking interferes with the 
hormone calcitonin responsible for calcium 
metabolism5 and may also decrease 
circulating endogenous oestrogen levels.28,29
Pathophysiology 
Effect of oestrogen on the skeletal system
Low plasma calcium, due to low intake or 
impaired calcium intestinal absorption, 
stimulates chief cells of the parathyroid gland 
to secrete parathyroid hormone (PTH).9 In 
order to maintain calcium homeostasis, PTH 
indirectly stimulates osteoclasts which engage 
in bone resorption causing calcium mobilisation 
from bone and thus bone demineralisation. 
Additionally, PTH upregulates the enzyme 
1-alpha-hydroxylase essential for the activation 
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of the inactive form of Vitamin D to its active 
form, 1,25-dihydroxycholecalciferol. The latter 
elevates calcium absorption in the intestine. 
PTH also acts on the kidneys to increase tubular 
calcium reabsorption. It has been proposed that 
sex steroids such as oestrogen, androgens and 
progesterone inhibit the activity of PTH on bone, 
decreasing bone resorption.14,30 Oestrogen has 
the ability to alter the sensitivity of bone to PTH 
without changing its sensitivity to other target 
organs, such as the gut and the kidneys.16
During menopause, as oestrogen production 
decreases, bone becomes more sensitive to 
PTH. As a consequence, the inhibition of PTH 
on bone resorption declines and for a certain 
level of PTH, higher calcium mobilisation from 
bone occurs. This leads to an increase in plasma 
calcium which in turn causes a decline in the 
level of PTH. Renal tubular resorption of calcium 
decreases causing higher urinary excretion 
of calcium while the production of 1-alpha 
hydroxylase decreases, causing a reduction of 
active vitamin D with less absorption of calcium 
from gut.18
In menopause, a decline in the body’s 
efficiency to make use of dietary calcium 
together with a decrease in calcium reabsorption 
from the renal tubule, stimulate bone 
remodelling in attempt to provide a constant 
amount of calcium to non-osseous tissues. As 
the majority of plasma calcium is derived from 
bone, there is a constant bone loss each year.18
Calcitonin is a hormone synthesised 
by the parafollicular cells of the thyroid 
gland in response to an increase in plasma 
calcium. Calcitonin has opposite effects to 
PTH. It suppresses both the production of 
new osteoclasts and it also inhibits their 
activity. Calcitonin causes less calcium tubular 
reabsorption in the kidneys and elevates urinary 
excretion of calcium.14 Oestrogen elevates 
calcitonin levels needed to prevent bone loss.18
Effect of oestrogen on fibrocartilage
Twenty percent of the spinal column height is 
attributable to the intervertebral disc. The roles 
of the intervertebral disc in permitting mobility 
of the spine and acting as a “shock absorber” are 
most compromised in osteoporotic compression 
fracture.31,32 
In pre-menopausal women, the nucleus 
pulposus and annulus fibrosus of the 
intervertebral disc contain collagen type IV, 
II and IX, elastin, glycosaminoglycans and 
water.  These constituents provide visco-
elastic properties and a discoid anatomy to the 
intervertebral discs.30,32 As the woman advances 
in her postmenopausal years, a more pronounced 
difference in collagen types is observed.31
Menopause has an effect on connective 
tissue.31 Aging causes diminished circulation 
to the nucleus pulposus leading to a series 
of modifications in discs’ components. 
These variations include a decrease in 
glycosaminoglycans and elastin content, 
dehydration and formation of collagen types I, 
III and VI replacing previous collagen types. 
Disc fibrosis and degeneration cause loss of 
intervertebral disc height interfering with its 
function as a vital tissue pump.33
Diagnostic techniques for bone mass 
measurement
Radiographic techniques
In postmenopausal women, bone mineral 
density can vary according to the skeletal site.  
Postmenopausal women may present with normal 
bone mineral density in one part of the body 
and low bone mineral density in another body 
part. The primary site where bone loss occurs is 
the spine (L1 or L2-L4) as it is the region where 
the greatest trabecular bone remodelling occurs. 
In women up to 65 years of age, the ideal body 
region to measure bone mineral density should 
be the spine as it is the first site of bone loss.34,35 
BMD testing is advised in patients  with 
dual-energy X-ray absorptiometry (DXA) in 
women aged 65 years of age and older and in 
postmenopausal women younger than 65 years 
of age but with clinical risk factors for fracture. 
Patient should then have BMD testing at least 
every 2 years as follow-up.36,37
Several direct methods for measuring bone 
mineral densities are available.16 Dual-energy 
X-ray Absorptiometry (DXA) is mainly used to 
determine bone mass in the spine (mainly in the 
lumbar regions), the hip or the total skeleton.  
Dual-Photon Absorptiometry (DPA) uses a beam 
of photons with discrete energy peaks in which 
one of them is absorbed by soft tissue and the 
other by bone. DXA uses an X-ray beam with 
discrete energy peaks in which one of them 
is absorbed by soft tissue and the other by 
bone DXA is regarded as the gold standard 
for diagnosing postmenopausal osteoporosis 
as it provides both accurate and precise 
measurements.2,35
Interpreting a DXA bone density result
The different bone mineral density tests are 
generally reported in the form of a T-score or 
Z-score. The T-score, is the number of standard 
deviations (SD) by which the bone mineral 
density (BMD) of the patient (Equation 1) 
varies when compared to that of the average 
young adult (30 years old) of the same gender 
and ethnicity. The Z-score is the number of 
standard deviations the bone mineral density 
measurement varies when compared to a 
mean bone mineral density of the same age, 
gender and ethnicity (Equation 2). This score 
determines whether a secondary underlying 
cause is actually contributing to bone loss.6,35 
In accordance to the International Society 
for Clinical  Densitometry (ISCD),  the WHO 
classification shall only be recommended to be 
used in clinical practice for postmenopausal 
women and in men 50 years and older.38
Quantitative ultrasonography (QUS) is used 
to assess skeletal status of the calcaneous and 
the phalanges. As QUS makes use of ultrasound 
waves, no radiation load is involved, making it a 
safe and a non-invasive technique. QUS can also 
be used in conjunction with DXA to provide a  
better prediction of fracture risk.23,34,39 
Biochemical markers of bone turnover
Biomarkers are sensitive tools to assess bone 
resorption and formation. These are actually 
used to monitor treatment of osteoporotic 
patients rather than to diagnose osteoporosis 
itself. The level of biochemical markers 
fluctuate within few months following initiation 
Table 1: World Health Organisation (WHO) classification11  
T-score is equal or greater than -1 SD Normal
T score between  -1 SD to -2.4 SD Osteopenia
T-score is equal or lower than -2.5 SD Osteoporosis
T score =   BMD – population peak
 SD of population peak BMD 
Equation 1: T-score6
Z score = Patient’s BMD – population age-related
 SD of population age-related BMD
Equation 2: Z-score6
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of treatment. Postmenopausal women are 
characterised by an increase in bone resorption 
markers and a decline in bone formation 
makers indicating the extent of uncoupling 
of bone formation and resorption present in 
postmenopausal osteoporosis.6,40,41 
Biomarkers of bone formation represent 
osteoblastic activity and these are by-products 
of collagen synthesis, matrix proteins or 
osteoblastic enzymes.40 These biomarkers include 
serum total alkaline phosphatase, osteocalcin 
and procollagen type I. These markers can be 
measured directly from circulation by a serum or 
plasma sample.42
Biomarkers of bone resorption represent 
osteoclastic activity and are mainly degradation 
products of type I collagen.40  Fragments 
resulting from osteoclastic degeneration of bone 
as well as from disintegration of the organic 
matrix are used as biochemical markers for bone 
resorption.  These fragments generally possess 
post-translational modifications of collagen 
which make them useless for utilisation by 
the body.42 Disintegrated products resulting 
from enzymatic hydrolysis of type I collagen 
are among the most effective markers for bone 
resorption.41 These collagen degradation products 
are released in circulation and then excreted 
in urine.6 N-telopeptide, C-telopeptides and 
related pyridinoline cross-links of bone type I 
collagen are used as markers of bone resorption 
in osteoporosis.41
Fracture risk calculators 
New diagnostic techniques have been devised 
to assess the absolute risk of developing an 
osteoporotic fracture. FRAX® algorithm and 
the Garvan nomogram are web-based tools 
which integrate the clinical risk factors with 
BMD measured at the neck of the femur. FRAX® 
algorithm can predict a 10-year risk of hip 
fracture and other major osteoporotic fractures. 
The latter refers to a clinical spine, forearm, 
hip or humerus fracture. The fracture risk is 
calculated based on clinical risk factors with or 
without femoral neck BMD.35
Treatment
The primary goal of treating postmenopausal 
osteoporosis is to mediate bone repair, alleviate 
bone strength and decrease the frequency of 
both vertebral and non-vertebral fractures 
which account for significant morbidity and 
mortality.43,44,45
The management of postmenopausal 
osteoporotic women involves both 
pharmacological and non-pharmacologic 
treatments.43
Pharmacological interventions
Pharmacological therapy shall be considered 
in postmenopausal women and men aged 50 
years and older with history of hip or vertebral 
fracture, T-score of -2.5 or lower at the femoral 
neck or spine without any secondary causes 
and in patients with T-score between -1 and 
-2.5 at femoral neck or spine who have a 10 
year probability of hip fracture of  ≥3 or any 
osteoporotic fracture of ≥20% based upon 
the United states using the WHO FRAX.46 
As displayed in table 2, treatment can be 
categorised into antiresorptive drugs which 
delay bone resorption and anabolic drugs which 
promote bone formation.47 
•	 Hormone Replacement Therapy (HRT) 
Hormone replacement therapy involves 
the administration of physiologic levels 
of oestrogen and progestin to replace and 
artificially boost the hormones which decline 
during menopause.14 
Epidemiology shows that a short time 
frame with HRT decreases the occurrence 
of osteoporotic fractures.14 It has been 
determined that undergoing oestrogen 
therapy for 5 years reduces vertebral fracture 
by 60% whilst hip fracture can decline by 
50%.2,49
Generally by oestrogen treatment, bone 
turnover is reduced by half, decreasing 
postmenopausal bone loss and lowering 
the incidence of an osteoporotic fracture.50 
However, once treatment with HRT stops, 
oestrogen level declines and protection 
against osteoporosis is lost again. Most 
studies suggest that bone loss will progress 
at the same rate as before HRT treatment.   
Thus the accelerated bone loss during 
menopause is postponed by the duration of 
HRT treatment.2,14 
As long term duration of therapy 
is needed for the prevention of 
postmenopausal osteoporosis, HRT has 
been associated with various risks which 
limit its attraction as treatment option.19 
The long term adverse effects implicated 
for HRT include carcinoma mainly of the 
breast, endometrium and colorectal as well 
cardiovascular diseases such as coronary 
heart disease, cerebrovascular accident and 
pulmonary embolism.51,52 
Regulatory authorities state that HRT 
should not be used as first-line treatment  in 
prophylaxis as  long term risks may outweigh 
the potential benefits.6,40,45 Thus HRT should 
only be considered when other treatment 
options have proved to be unsuccessful.45,53,54 
•	 Teriparatide 
Teriparatide is a recombinant synthetic 
form of the natural human hormone, PTH 
which is administered subcutaneously.  It 
is known to enhance bone formation by 
activating osteoblasts and increase bone 
mineral density.14,55 Teriparatide enhances 
calcium intestinal absorption as well as 
calcium reabsorption from the kidney. With 
its anabolic action, it decreases significantly 
vertebral and non-vertebral fractures but not 
hip fracture.56 Teriparatide  is used mainly 
in severe osteoporotic patients with a high 
fracture risk.2
•	 Bisphosphonates 
Bisphosphonates are anti-resorptive drugs2 
which act by adsorbing onto hydroxyapaptite 
crystals in bone and exert a potent 
inhibitory effect on bone resorption rate 
maintaining BMD. Bisphosphonates can be 
used both as a prophylaxis and as treatment 
for osteoporosis as they decrease the rate of 
bone loss and fracture risk in osteoporotic 
patients.53 In fact, bisphosphonates decrease 
both vertebral and non-vertebral fractures 
up to 50% while hip fractures are decreased 
by 20%. Bisphosphonates also enhance BMD 
at both the hip and the spine in a dose-
dependent way.57
Bisphosphonates can be divided into 
two main groups: non-nitrogen containing 
bisphosphonates and nitrogen containing 
Table 2: Pharmacological agents48
Anti-resportive Anabolic Anti-resorptive & anabolic
HRT
Calcitonin
Bisphosphonates
SERMs
Cathepsin K inhibitor 
(odanacatib)
Denosumab
Teriparatide
Parathyroid hormone
Strontium ranelate
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bisphosphonates. Etidronate is a non-
nitrogen containing bisphosphonate.   
The nitrogen containing bisphosphonates 
include alendronate, risedronate and 
ibandronate. Alendronate, risedronate 
and etidronate are most clinically used 
in corticosteroid-induced osteoporosis to 
decrease both vertebral and non-vertebral 
fractures.6, 55 Osteonecrosis of the jaw 53   
and gastro-intestinal damage are among 
the adverse effects which limit the use of 
oral bisphosphonates.19,56 Administering  
bisophosphonates such as ibadronate and 
zoledronic acid intravenously enhance their 
potency in inhibiting bone remodelling 
however they are linked to transient flu-like 
symptoms and self-limited myalgia.57
•	 Strontium ranelate 
Strontium ranelate is a dual action bone 
agent as it has an anti-resorptive and 
anabolic action.56 It inhibits the osteoclasts 
recruitment and augments osteoblasts 
proliferation and differentiation.58 Thus, with 
strontium ranelate therapy bone resorption 
is suppressed while bone formation is 
stimulated.  Both hip and vertebral fractures 
are decreased with such a treatment.56 
•	 Selective oestrogen receptor modulators 
(SERMs) 
SERMs  are non-steroidal compounds  with 
tissue-specific activity having oestrogenic 
effects in certain tissues and anti-
oestrogenic effects in others. They bind 
to oestrogen  receptors within the bone 
and  change the receptor conformation to 
aid in the binding of co-regulatory proteins  
and activate target genes.59 Raloxifene is 
an anti-resorptive agent which prevents 
osteoporosis-related vertebral fracture. It 
decreases vertebral fractures by 30-50% 
and increases bone mineral density at 
the hip and the spine by 0.5% to 1.0% 
respectively.6,34,45 
•	 Calcitriol  
Calcitriol (1,25-dihydroxycholecalciferol)  
is  an active vitamin D metabolite used to 
treat low calcium levels in postmenopausal 
women. Conflicting data has emerged 
regarding the effect of calcitriol on bone.6 
Studies have shown that calcitriol aids in 
calcium intestinal absorption and reduces 
the rate of vertebral fracture whereas it has 
no effect on hip fracture.45
•	 Vitamin D  and calcium supplementation 
During infancy, childhood and adolescence 
calcium intake is of utmost importance 
as calcium is required for peak bone mass 
to be achieved. Postmenopausal women 
have the highest calcium requirements 
with a recommended daily intake of at least 
1000-1200mg. Providing adequate amount of 
dietary or supplemental calcium and vitamin 
D to postmenopausal women particularly 
the elderly serves as a baseline treatment of 
postmenopausal osteoporosis56 as a decrease 
in intestinal calcium absorption is noted with 
advancing age.60 
Calcium supplementation may lower 
the rate of bone loss following two years 
of treatment however during the initial 5 
years of menopause, it exerts little effect 
on bone loss as it can be attributed to the 
decline in oestrogen synthesis.18,47 Calcium 
supplementation is regarded as an adjunct 
to other treatment regimens unless sufficient 
dietary intake is ensured.56
Institutionalised or housebound patients 
who are rarely exposed to the natural sunlight 
and persons who chronically use sunscreen 
products particularly with high sun protection 
factors may possess vitamin D deficiency. 
Thus Vitamin D supplementation is essential 
in these patients. Vitamin D may decrease 
the risk of hip and non-vertebral fractures in 
ambulatory elderly patients only if an oral 
supplementation of 700-800IU is administered 
each day.6,61 
Vitamin D and calcium supplementation 
increase BMD and decrease the risk of fracture. 
The latter is negated by some randomised 
controlled clinical trials.57 In additional to 
calcium, other elements including copper, 
boron, magnesium, manganese, phosphorus, 
potassium and zinc are associated with 
improving bone health. Aluminium, cadmium 
and lead appear to affect BMD negatively.62 
•	 Fluoride  
The use of fluoride in the treatment of 
osteoporosis is argumentative.2,63 Fluoride 
treatment activates osteoblasts resulting in 
bone formation in trabecular part of bone 
while long term treatment enhances the mass 
of the central skeleton.16 
•	 Denosumab 
Denosumab is a Receptor Activator of Nuclear 
Factor kappa-β ligand (RANKL) - targeted 
monoclonal antibody.64 By binding with high 
affinity and high-specificity to RANK, it 
suppresses the binding of RANKL to receptor 
Activator of Nuclear Factor kappa-β (RANK) 
64,65  and hence,  blocks the development, 
differentiation, activation and survival of 
osteoclasts. This leads to a decline in bone 
resorption and promotes BMD.  Its fast 
onset of action and  its  constant  prolonged 
reversible activity  make denosumab a better 
therapeutic agent than the current treatment 
options.65-68  
 Administration of denosumab 
subcutaneously once every 6 months for 36 
months decreases the risk of vertebral, non-
vertebral and hip fractures in osteoporotic 
women.68 However, two major drawbacks 
of using denosumab as a treatment of 
postmenopausal osteoporosis are the potential 
formation of infections and higher risk of 
malignancy.69
•	 Calcitonin 
Calcitonin is a peptide hormone synthesised 
by the thyroid gland. Calcitonin has been 
withdrawn for the treatment of osteoporosis 
as it has been found that long term use 
increases the risk of cancer.70 
Potential novel pharmacological agents
•	 Cathepsin K inhibitors 
Cathepsin K is an acid activated cysteine 
protease,71 required for the degradation of 
the organic matrix.72 It exerts its function 
specifically on bone type I collagen under 
acidic conditions.73,74
Odanacatib is the most advanced 
cathepsin K inhibitor undergoing clinical 
trials.47 It decreases bone resorption not by 
decreasing the presence of osteoclasts or 
their activity but by selectively suppressing 
the degradation of matrix protein. Substantial 
dose-related increase in BMD was observed 
in lumbar spine, total-hip, femoral neck and 
one-third of the radius during the second year 
of treatment. Headaches, flu-like symptoms 
and abdominal discomfort are amongst the 
adverse effects of odanacatib.74,75
The novel cathepsin-K inhibitor, ONO-
5334 is still undergoing clinical investigation. 
It seems to enhance BMD in the lumbar spine 
with an improved effect on the femur and 
induces no severe side effects.47,76,77
•	 Calcilytic drugs (MK-5442) 
MK-5442 is a calcilytic drug which targets 
calcium sensing receptors (CaSR antagonist) 
of the parathyroid glands.  It provokes a 
hypocalcaemic environment hence stimulating 
pulsed PTH secretion resulting in a net 
anabolic situation. MK-5442 is still currently 
undergoing clinical trials.47,78,79 MK-5442 has 
not been shown to improve BMD in patients 
already on bisphosphonates therapy and 
hence should not be considered to be used in 
combination with bisphosphonates.80 
•	 Wnt /β-catenin pathway antagonists  
Osteoblastic differentiation and subsequently 
bone formation can be induced by Wnt-
dependent nuclear accumulation of β-catenin. 
Possible future therapeutic agents include 
BHQ-880 which suppress Wnt pathways by 
Dickkopf-1 antibodies and Romosozumab 
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and blosozumab by targeting sclerostin 
antibodies. These medications are still under 
study as potential therapeutic agents for 
postmenopausal osteoporosis.47,80
Alternative and complementary therapy 
•	 Phytoestrogens 
As some women have fear of the 
adverse effects produced by some drugs, 
alternative methods to prevent and treat 
postmenopausal osteoporosis are sought. 
Phytoestrogens are plant-derived compounds 
which function like oestrogen. Classes of 
phytoestrogens include isoflavones present 
in soy beans and soy products, lignans 
present in oilseeds and coumestans found in 
alfalfa and red clover. These phytoestrogens 
exert a protective effect on bone by 
retarding bone resorption and maintaining 
skeletal integrity. Phytoestrogens 
promote osteogenesis when taken at low 
concentrations and suppress osteogenesis at 
higher doses.6 
Conclusion
A high index of clinical suspicion of 
postmenopausal osteoporosis is required as 
it may go unnoticed until a fracture occurs. 
Lifestyle measures that include the adequate 
intake of calcium and vitamin D, 30-minutes 
exercise at least three times a week and smoking 
cessation and limit  alcohol intake aim to reduce 
bone loss in postmenopausal women. Counseling 
on fall prevention to women at risk shall be 
employed.  The choice of pharmacological 
therapy depends on multiple factors including 
the severity of the osteoporosis and the 
risk for fractures.  Preventing and treating 
post-menopausal osteoporosis decreases the 
social, emotional and financial burden of an 
osteoporotic fracture.46 
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